A two-pronged approach | Addiction Professional Magazine Skip to content Skip to navigation

A two-pronged approach

September 1, 2010
by Alison Knopf
| Reprints

Drug and alcohol testing, commonly used in the workplace as a hiring and firing tool, is used in substance abuse treatment settings for a very different reason: helping patients recover. In substance abuse treatment programs, testing is used for two purposes: to establish a baseline level for any recent substance use by the patient and to monitor patients who are involved in ongoing substance abuse treatment. In neither case is the purpose to “catch” someone abusing drugs or alcohol, because the patient has already asked for help.

There are strict federal regulations for the use of drug testing in the workplace, but no rules-with the narrow exception of methadone and buprenorphine treatment-for use in substance abuse treatment programs, says Robert Lubran, director of the division of pharmacologic therapies at the federal Center for Substance Abuse Treatment (CSAT), part of the Substance Abuse and Mental Health Services Administration (SAMHSA). “Programs are pretty much on their own” when it comes to deciding what kinds of tests to use, and what to test for, he tells Addiction Professional.

But urine is definitely the kind of specimen that is preferred-in part because of the scientific rigor labs have developed as a result of the federal workplace testing program-considering it passed the muster of the U.S. Supreme Court.

SAMHSA, together with the FDA and the Health Resources and Services Administration, is developing a physician's guide for the selection of drug and alcohol testing, says Lubran. He says that the guide will be available later in 2010 and can be expected to help doctors with screening, brief intervention, and referral to treatment (SBIRT) for substance use disorders, a key component of the national drug strategy issued this year by the White House.

Urine testing update

The “classic five” drugs that are tested for in the workplace via urine testing are heroin, cocaine, PCP, methamphetamine, and cannabinoids (marijuana and hashish), says Robert L. Stephenson II, director of the division of workplace programs at the Center for Substance Abuse Prevention (CSAP), also part of SAMHSA.

“When we created the workplace program 22 years ago, we made a deliberate decision not to test for prescription medications so that we did not get between a patient and a physician,” says Stephenson. Today, the situation is somewhat different. Given the increasing abuse of prescription medications, drug testing programs cannot be limited to “illegal” drugs. Legal opiates-fentanyl, oxycodone, methadone, codeine, and morphine, for example-are increasingly popular as drugs of abuse, instead of or in addition to illegal opiates like heroin. Stephenson points out that if a substance abuse program utilizes lab services, the program must clearly explain that the setting for its testing is a treatment center, not a workplace.

There are two basic kinds of urine tests: the screen (done either on site or in a lab), which can give a negative or a “presumptive positive,” and a second more expensive and definitive confirmation test (always done in a lab) on that initial test.

Instead of an expensive confirmation test, in the treatment setting, the confirmation will usually be the admission of the patient, says Stephenson. “They will say that they relapsed or used,” he says. If, however, the patient doesn't admit to drug use, the treatment provider should send the urine off to an accredited lab for the confirmation testing.

“Point of care” tests, in which the treatment program tests the urine immediately instead of sending it out to a laboratory, can have error rates of as high as 30-40 percent, says Stephenson. “In the real world, some programs might discharge patients for positive tests,” he says, and strongly recommends against taking any action at all based on a positive point-of-care test that the patient denies.

Workplace tests tend to have high cutoff levels for a positive, and Stephenson strongly urges that treatment programs use low cutoff levels to detect even the slightest level of drug use.

New saliva test options

The “next agenda” beyond urine testing is oral fluid testing, says CSAT's Lubran, adding that methadone treatment programs are already using saliva testing.

Intercept, the first oral fluid drug test, was cleared by the FDA for use in 2000. Since then, oral testing has seen significant advances, explained Ron Ticho, senior vice president for corporate communication for OraSure Technologies, the Bethlehem, Pa.-based manufacturer of the Intercept drug test. Currently, this test may be used to detect 10 different drugs, and, over the course of the next few months, several more drugs will be added. One saliva specimen is taken, with various “microplates” used for the testing.

The collection is done on site, and the sample is stored in a container provided by OraSure and then sent to the lab. Various labs are set up for doing the testing, with results in 72 hours, says Ticho.

CDT marks heavy drinkers

Researchers are exploring the use of “biomarkers” to test for very heavy drinking, based not on the presence of alcohol in the body, but on its effects on the body. Carbohydrate-deficient transferring (CDT) is one such test, explains Raymond Anton, MD, director of the Clinical Neurobiology Laboratory at Medical University of South Carolina in Charleston.

Anton became interested in CDT testing because in the course of his alcohol research, “it became clear that people don't accurately report what they drink.” He says that anyone who tests positive on the CDT test is likely to have been drinking “at least five to six drinks a day for a few weeks.”